Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Boswellia 450 mg Ingredients & Drug Interactions

by Solaray

Capsule Category: Botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Boswellia 450 mg is a dietary supplement by Solaray with 2 active ingredients. Its ingredients are commonly taken for osteoarthritis joint pain, rheumatoid arthritis, inflammation.Based on those ingredients, 1,012 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Boswellia, Devil's Claw. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Boswellia 450 mg by Solaray

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • “Boswellia” is listed as a grouped ingredient — the label gives one combined amount (450 mg) without saying how much of each component you get.

This product contains two active ingredients: Boswellia and Boswellic Acid, which are thought to support joint and connective tissue function. The capsule also includes three inactive ingredients — cellulose, magnesium stearate, and silica — as binders and fillers to hold the formula together.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Joint health.
  • We looked for evidence on: Osteoarthritis, Back pain, Rheumatoid arthritis (RA), Tendinopathy, Joint pain, Joint stiffness — and 1 related terms.
  • The strongest evidence on file: Devil's Claw is rated "Possibly Effective" for Back pain (Natural Medicines).
  • Also on file: Devil's Claw is rated "Possibly Effective" for Osteoarthritis.
  • Also on file: Devil's Claw is rated "Insufficient Reliable Evidence To Rate" for Rheumatoid arthritis (RA), Tendinopathy.

Devil's Claw, one of the active components, is rated Possibly Effective for back pain and osteoarthritis based on available evidence. The evidence for atherosclerosis is insufficient to rate.

We hold no effectiveness data for Boswellic Acid or the broader Boswellia ingredient itself, so we can't say how well those parts work for any condition.

The evidence, ingredient by ingredient Boswellia Serrata Devil's Claw

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Devil's Claw is generally well tolerated for short-term use in healthy adults, but it does cause digestive upset in some people. The most common side effects are allergic skin reactions, diarrhea, and indigestion.

Gastrointestinal complaints were reported in 9% to 18% of patients in trials, and diarrhea specifically in about 8%. Rarely, gastrointestinal bleeding has occurred.

You may also experience headache, dizziness, or taste changes, though it's unclear if these are actually caused by the ingredient. Avoid this product if you're pregnant — Devil's Claw may affect the uterus and safety hasn't been established.

Do not take it while breastfeeding; there isn't enough safety information. We hold no pregnancy or breastfeeding safety data for Boswellic Acid or Boswellia itself.

Side effects, ingredient by ingredient Boswellia Serrata Devil's Claw

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Devil's Claw.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs.
  • For scale: 805 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before you start, double-check if you take blood thinners like warfarin (Coumadin) — Devil's Claw may increase their effect. Also flag any medications broken down by your liver's CYP2C19, CYP2C9, or CYP3A4 enzymes (a huge category including some statins, heart drugs, and blood pressure medications).

Finally, if you take H2-blockers or PPIs for acid reflux or stomach ulcers, Devil's Claw may make them less effective. Use the checker on this page to run through your full medication list.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

If you have back pain or osteoarthritis and aren't pregnant or breastfeeding, this may be worth considering — but only if you don't take blood thinners or medications that depend on liver enzyme pathways like CYP3A4. Anyone on prescription medications should check their exact drugs against the interaction tool below before starting.

Talk to your pharmacist or doctor if you have a history of gastrointestinal bleeding or if you take acid-suppressing medications.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Sep 25, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Boswellia 450 mg, straight from the product label.

Brand Solaray
Barcode (UPC) 076280399059
Net contents 60 VegCap(s)
Market status On market
Date entered into DSLD Sep 25, 2025
DSLD ID 339084
Product type Botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Women (not pregnant or lactating), Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Boswellia 450 mg by Solaray, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 VegCap(s)
Maximum serving Sizes:
1 VegCap(s)
Servings per container
60
UPC/BARCODE
076280399059
IngredientAmount% DV
Boswellic Acid290 mg--
Boswellia450 mg--
Devil's Claw125 mg--

Other ingredients: Cellulose, Magnesium Stearate, Silica

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Brand IP Statement(s)

Solaray Est. 1973 A brighter way 1973

Formula

65% Boswellic acids

Discussion: Boswellia, also known as Indian frankincense, is a resin extract taken from the boswellia serrata tree. The active phytochemicals found in boswellia, known as boswellic acids, may support overall joint health.

Formulation

Joint health

Non GMO Project Verified nongmoproject.org

Vegan

FDA Statement of Identity

Dietary Supplement

Seals/Symbols

Non GMO Project Verified nongmoproject.org Lab verified Vegan

General Statements

Vital extracts Since 1973, we've scoured the globe for the highest quality ingredients, connecting you with the most efficacious supplements that help you live brighter & embrace the moments that matter most.

100% PCR bottles

Precautions

Warning: Do not use if safety seal is broken or missing. Keep your licensed health care practitioner informed when using this product. Directions: Use only as directed.

Keep out of reach of children.

Do not use if you are pregnant.

Suggested/Recommended/Usage/Directions

Directions: Use only as directed. Take 1 VegCap daily with a meal or glass of water.

Storage

Store in a cool, dry place.

FDA Disclaimer Statement

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

See for yourself

Boswellia 450 mg by Solaray label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Boswellia 450 mg by Solaray

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 VegCap(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Boswellia

Interacts with
952 drugs
450 mg per serving Form: Boswellia Serrata Gum Extract, Boswellia serrata Resin Extract

Boswellia serrata is a tree resin used in traditional medicine, mainly for joint pain and inflammation. Some studies suggest it may help with osteoart...

Boswellia monograph & interactions
  • › Boswellic Acid

Devil's Claw

Interacts with
804 drugs
125 mg per serving Form: Harpagophytum procumbens extract, Harpagophytum zeyheri Root Extract

Devil's claw is a southern African plant used mainly for arthritis and back pain, and some studies suggest it may help ease these types of discomfort....

Devil's Claw monograph & interactions

Other (inactive) ingredients: Cellulose, Magnesium Stearate, Silica. These complete the product’s ingredient list but are not active constituents.

Interaction report

Boswellia 450 mg by Solaray Drug Interactions

Want to check YOUR meds against Boswellia 450 mg?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,012Drugs
952 Moderate 60 Minor

Ingredients driving the most interactions

Boswellia 952

Each ingredient & the kinds of drugs it affects

For each ingredient in Boswellia 450 mg with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Boswellia6 drug types · 952 drugs

Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP1A2 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP1A2 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2C19 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2C19 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2C9 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2C9 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2D6 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2D6 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, Boswellia serrata might increase or decrease the levels and clinical effects of CYP3A4 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP3A4 enzymes. Other in vitro research shows that Boswellia serrata extract inhibits CYP3A4 enzymes at most concentrations, although it may modestly induce enzyme activity at low concentrations.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, Boswellia serrata might alter the effects of immunosuppressive drugs.
Some in vitro research suggests that Boswellia serrata extracts might inhibit mediators of autoimmune disorders such as leukotrienes and reduce production of antibodies and cell-mediated immunity. However, other in vitro research suggests that, when coupled with calcium ions, boswellic acids containing the keto group have immunostimulant properties within specific cell signaling pathways.

Likelihood Possible Evidence D

Devil's Claw7 drug types · 804 drugs

Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, devil's claw might increase levels of drugs metabolized by CYP2C19.
In vitro research shows that devil's claw might inhibit CYP2C19, although this has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, devil's claw might increase levels of drugs metabolized by CYP2C9.
In vitro research shows that devil's claw might inhibit CYP2C9, although this has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, devil's claw might increase levels of drugs metabolized by CYP3A4.
In vitro research shows that devil's claw might inhibit CYP3A4, although this has not been reported in humans.

Likelihood Possible Evidence D
Warfarin (Coumadin)

Theoretically, Devil's claw might increase the activity of warfarin.
In one case report, purpura occurred in a patient taking warfarin and devil's claw concurrently. This might indicate over-anticoagulation. It is unclear if this was due to Devil's claw or other contributing factors.

Likelihood Possible Evidence D
H2-Blockers

Theoretically, devil's claw might decrease the effectiveness of H2-blockers.
Devil's claw has been reported to increase stomach acid, which might interfere with the effects of H2-blockers.

Likelihood Possible Evidence D
P-Glycoprotein Substrates

Theoretically, devil's claw might increase levels of P-glycoprotein substrates.
In vitro research shows that devil's claw inhibits P-glycoprotein, which transports many drugs out of cells. This might increase intracellular levels of P-glycoprotein substrates, although it is unclear if this effect would be clinically important.

Likelihood Possible Evidence D
Proton Pump Inhibitors (Ppis)

Theoretically, devil's claw might decrease the effectiveness of PPIs.
Devil's claw has been reported to increase stomach acid, which might interfere with the effects of PPIs.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Boswellia 450 mg, from the product label.

Solaray

See all Solaray products
Name
Solaray
City
Salt Lake City
State
UT
ZipCode
84101
Phone Number
800-538-5888
Web Address
www.solaray.com
Pharmacist Counseling Corner

Boswellia 450 mg by Solaray: Common Questions

Does Boswellia 450 mg by Solaray interact with any medications?
Yes. Based on its ingredients, Boswellia 450 mg has a known interaction with 1,012 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Boswellia 450 mg contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I'm pregnant or breastfeeding?
No. The safety data advises against it during pregnancy because Devil's Claw may affect the uterus and safety hasn't been established. Do not take it while breastfeeding either — there isn't enough safety information. Talk with your doctor or pharmacist about alternatives.
What are the most common side effects?
Digestive upset is most common — especially diarrhea, indigestion, and allergic skin reactions. In trials, gastrointestinal complaints were reported in 9% to 18% of people taking devil's claw. Rarely, gastrointestinal bleeding has occurred, so stop and call your doctor if you notice black stools or other signs of bleeding.
Does this actually work for back pain?
Devil's Claw is rated Possibly Effective for back pain and osteoarthritis based on the available evidence. That means some studies suggest it may help, but more research would strengthen the case. Results vary from person to person.
Why should I check my medications with your tool?
Devil's Claw interacts with blood thinners and with hundreds of medications metabolized by your liver. Taking it alongside those drugs could change how they work — either by raising their levels or making acid-suppressing medications less effective. The checker lets you see if yours are affected.
What are Boswellia and Boswellic Acid supposed to do?
They're thought to support joint and connective tissue function. However, we hold no effectiveness data for those specific ingredients in our system, so we can't tell you how well they work on their own for any condition.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Boswellia 450 mg is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Boswellia 450 mg label
Sources

Sources & How We Checked

Boswellia 450 mg's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 34 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Boswellia Serrata 16 references
  1. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998;3:511-4.
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine 2003;10:3-7. PubMed
  4. Liu JJ, Nilsson A, Oredsson S, et al. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002;23:2087-93. PubMed
  5. Wildfeuer A, Neu IS, Safayhi H, et al. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Arzneimittelforschung 1998;48:668-74.
  6. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391-5. PubMed
  7. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin. Arthritis Res Ther 2008;10:R85.
  8. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci 2010;7:366-77.
  9. Ernst E. Frankincense: systematic review. BMJ 2008;337:a2813. PubMed
  10. Kirste S, Treier M, Wehrle SJ, et al. Boswellia serratea extract acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 2011;117:3788-95.
  11. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006;111 PubMed
  12. Altmann A, Poeckel D, Fischer L, et al. Coupling of boswellic acid-incuded Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes. Br J Pharmacol 2004;141:223-32.
  13. El Fortia, M., Badi, H., Elalem, Kh, Kadiki, O., and Topov, Y. Olibanum bezoar: complication of a traditional popular medicine. East Mediterr.Health J 2006;12(6):927-929.
  14. Meshkat S, Mahmoodi Baram S, Rajaei S, et al. Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injury. Brain Inj 2022;36(4):553-559. PubMed
  15. Haron MH, Dale O, Martin K, et al. Evaluation of the Herb-Drug Interaction Potential of Commonly Used Botanicals on the US Market with Regard to PXR- and AhR-Mediated Influences on CYP3A4 and CYP1A2. J Diet Suppl 2022. PubMed
  16. Valente IVB, Garcia D, Abbott A, et al. The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer. Breast Cancer Res Treat 2024;204(3):521-530. PubMed

See these in context on the Boswellia Serrata monograph →

Devil's Claw 18 references
  1. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  2. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997;17:342-56.
  3. Chantre P, Cappelaere A, Leblan D, et al. Efficacy and tolerance or Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000;7:177-83.
  4. Chrubasik S, Thanner J, Kunzel O, et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002;9:181-94. PubMed
  5. Circosta C, Occhiuto F, Ragusa S, et al. A drug used in traditional medicine: Harpagophytum procumbens DC. II. Cardiovascular activity. J Ethnopharmacol 1984;11:259-74. PubMed
  6. Grahame R, Robinson BV. Devils's claw (Harpagophytum procumbens): pharmacological and clinical studies. Ann Rheum Dis 1981;40:632. PubMed
  7. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  8. Wegener T, Lupke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC). Phytother Res 2003;17:1165-72.
  9. Chrubasik S, Kunzel O, Thanner J, et al. A 1-year follow-up after a pilot study with Doloteffin for low back pain. Phytomedicine 2005;12:1-9. PubMed
  10. Romiti N, Tramonti G, Corti A, Chieli E. Effects of Devil's Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein. Phytomedicine 2009;16:1095-100. PubMed
  11. Chrubasik, S., Junck, H., Breitschwerdt, H., Conradt, C., and Zappe, H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double- blind study. Eur.J Anaesthesiol. 1999;16(2 DOI
  12. Laudahn, D. and Walper, A. Efficacy and tolerance of Harpagophytum extract LI 174 in patients with chronic non-radicular back pain. Phytother.Res. 2001;15(7):621-624.
  13. Belaiche P. Etude clinique de 630 cas d'artrose traites par le nebulisat aqueux d'Harpagophytum procumbens (Radix). Phytotherapy 1982;1:22-28.
  14. Chrubasik S, Model A, Black A, and et al. A randomized double-blind pilot study comparing Doloteffin® and Vioxx® in the treatment of low back pain. Rheumatology 2003;42:141-148.
  15. Cuspidi C, Sala C, Tadic M, et al. Systemic hypertension induced by Harpagophytum procumbens (devil's claw): a case report. J Clin Hypertens (Greenwich) 2015;17(11):908-10.
  16. Mahomed IM, Ojewole JAO. Oxytocin-like effect of Harpagophytum procumbens [Pedaliacae] secondary root aqueous extract on rat isolated uterus. Afr J Trad CAM 2006;3(1):82-89.
  17. Carvalho RR, Donadel CD, Cortez AF, Valviesse VR, Vianna PF, Correa BB. J Bras Nefrol. 2017 Mar;39(1):79-81.
  18. Anon. Devil's claw root: ulcers and gastrointestinal bleeding. Prescrire Int 2013;22(144):296.

See these in context on the Devil's Claw monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring